Reslizumab | Consortium of Eosinophilic Gastrointestinal Disease Researchers

Skip to main content

Search

Join Our Contact Registry

Header Social Media

Our Research
Patients and Families
Researchers and Clinicians
CEGIR Awards
News and Events
- Events
- Latest News
About Us

An NIH-Funded Rare Diseases Clinical Research Network Consortium

A monoclonal antibody medication that works by reducing a certain type of white blood cell that may contribute to asthma.

Footer

Web Policies
Rare Diseases Clinical Research Network
Genetic and Rare Diseases Information Center
Members Login
Contact Us

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is part of the Rare Diseases Clinical Research Network (RDCRN), which is funded by the National Institutes of Health (NIH) and led by the National Center for Advancing Translational Sciences (NCATS) through its Division of Rare Diseases Research Innovation (DRDRI). CEGIR is funded under grant number U54AI117804 as a collaboration between NCATS, the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This website is hosted by the network’s Data Management and Coordinating Center at Cincinnati Children’s Hospital Medical Center, which is funded by NCATS and the National Institute of Neurological Disorders and Stroke (NINDS) under grant number TR002818. The content of this website is solely the responsibility of the CEGIR administrative coordinating center at Cincinnati Children’s Hospital Medical Center and does not necessarily represent the official views of the NIH.

social media